Order Article Reprints

Takahashi E, Sawabuchi T, Homma T, Fukuda Y, Sagara H, Kinjo T, Fujita K, Suga S, Kimoto T, Sakai S, et al. Clinical Utility of SARS-CoV-2 Antibody Titer Multiplied by Binding Avidity of Receptor-Binding Domain (RBD) in Monitoring Protective Immunity and Clinical Severity. Viruses. 2023; 15(8):1662. https://doi.org/10.3390/v15081662

Takahashi, Etsuhisa, Takako Sawabuchi, Tetsuya Homma, Yosuke Fukuda, Hironori Sagara, Takeshi Kinjo, Kaori Fujita, Shigeru Suga, Takashi Kimoto, Satoko Sakai, and et al. 2023. "Clinical Utility of SARS-CoV-2 Antibody Titer Multiplied by Binding Avidity of Receptor-Binding Domain (RBD) in Monitoring Protective Immunity and Clinical Severity" Viruses 15, no. 8: 1662. https://doi.org/10.3390/v15081662

Takahashi, E., Sawabuchi, T., Homma, T., Fukuda, Y., Sagara, H., Kinjo, T., Fujita, K., Suga, S., Kimoto, T., Sakai, S., Kameda, K., & Kido, H. (2023). Clinical Utility of SARS-CoV-2 Antibody Titer Multiplied by Binding Avidity of Receptor-Binding Domain (RBD) in Monitoring Protective Immunity and Clinical Severity. Viruses, 15(8), 1662. https://doi.org/10.3390/v15081662